2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170498
    GABA-A Receptor Ligand-1 3076335-23-1 98%
    GABA-A Receptor Ligand-1 (Compound 4) is a ligand for GABA-A receptor with a pKi of 7.27. GABA-A Receptor Ligand-1 reduces mitochondrial dysfunction, promotes neurite outgrowth and neuronal regeneration. GABA-A Receptor Ligand-1 exhibits neuroprotective efficacy in rats ischemic stroke models.
    GABA-A Receptor Ligand-1
  • HY-170499
    VU6024578 98%
    VU6024578 (BI02982816) is a selective, orally active positive allosteric modulator (PAM) for metabotropic glutamate receptor (mGluR1), that activates human mGluR1 and rat mGluR1 with EC50 of 54 nM and 46 nM. VU6024578 exhibits antipsychotic activity in rats amphetamine-induced hyperactivity models and MK-801 (HY-15084B)-induced novel object recognition (NOR) models. VU6024578 is blood brain barrier penetrable.
    VU6024578
  • HY-170509
    Ferroptosis-IN-17 98%
    Ferroptosis-IN-17 (Compound 18) is a ferroptosis (Ferroptosis) inhibitor with an EC50 value of 0.57 μM. Ferroptosis-IN-17 reduces intracellular ferrous ion accumulation, lipid peroxidation, and effectively restores the levels of glutathione (GSH) and glutathione peroxidase 4 (GPX4). Ferroptosis-IN-17 shows good solubility and significant metabolic stability in rat plasma. Ferroptosis-IN-17 is promising for research in tumor suppression, neurodegenerative diseases, and cardiovascular diseases.
    Ferroptosis-IN-17
  • HY-170531
    SR 142948-C3-NHMe 1613265-52-3 98%
    SR 142948-C3-NHMe is the methylated SR 142948 (HY-107664).
    SR 142948-C3-NHMe
  • HY-170532
    NLRP3-IN-63 3064696-02-9 98%
    NLRP3-IN-63 (Compound 7) is an inhibitor for NLRP3, that inhibits the NLRP3 activation with an EC50 of 13 nM.
    NLRP3-IN-63
  • HY-170553
    ZPD-2 98%
    ZPD-2 inhibits the aggregation of C-terminally truncated and full-length α-synuclein. ZPD-2 inhibits the formation and fibrillation of α-Syn, thereby preventing its propagation. ZPD-2 can be used in research of Parkinson's disease.
    ZPD-2
  • HY-170560
    AChE/hCA I-IN-1 155140-19-5 98%
    AChE/hCA I-IN-1 (Compound L3) is the inhibitor for acetylcholinesterase (AChE) and carbonic anhydrase (CA), that inhibits AChE, hCA I and hCA II with IC50 of 302, 265 and 283 nM, respectively.
    AChE/hCA I-IN-1
  • HY-170561
    AChE/BuChE-IN-6 98%
    AChE/BuChE-IN-6 (Compound 11f) is an inhibitor of AChE and BuChE, with IC50 values of 1.24 and 1.85 μg/mL, respectively. AChE/BuChE-IN-6 also exhibits strong DPPH free radical scavenging activity (IC50 = 3.15 μg/mL). In vivo toxicity studies indicate that AChE/BuChE-IN-6 is safe, showing no significant differences in blood and biochemical markers compared to the control group after long-term administration, and no abnormalities were observed in liver and kidney tissues. AChE/BuChE-IN-6 holds promise for research into Alzheimer's disease.
    AChE/BuChE-IN-6
  • HY-170562
    STEP-IN-1 3098824-77-9 98%
    STEP-IN-1 (Compound 14b) is a potent and selective STEP inhibitor with an IC50 of 5.27 μM. STEP-IN-1 has a neuroprotective effect, which can protect nerve cells from glutamate-induced toxicity, reduce cellular ROS accumulation, and inhibit apoptosis. STEP-IN-1 can be used in the study of neurodegenerative diseases.
    STEP-IN-1
  • HY-170578
    SIRT2-IN-17 98%
    SIRT2-IN-17 (compound Z18) is a potent SIRT2 inhibitor. SIRT2-IN-17 reduces the expression of α-SMA and p-Smad2/3.
    SIRT2-IN-17
  • HY-170583
    hAChE-IN-10 3058182-98-9 98%
    hAChE-IN-10 (Compound ET11) is the inhibitor for human acetylcholinesterase (AChE) with an IC50 of 6.34 nM. hAChE-IN-10 scavenges free radicals, and exhibits antioxidant activity. hAChE-IN-10 exhibits metal chelating activity, inhibits Cu2+-induced Aβ1-42 aggregation, reduces the formation of amyloid plaques, and exhibits neuroprotective activity. hAChE-IN-10 ameliorates the Scopolamine (HY-N0296)-induced cognitive impairment in mouse models.
    hAChE-IN-10
  • HY-170654
    Opioid receptor antagonist 1 1559075-15-8 98%
    Opioid receptor antagonist 1 (Compound 10) is an Orvinol (HY-D0168)-based opioid receptor antagonist. Opioid receptor antagonist 1 has antagonistic activity to the analgesic properties of Morphine.
    Opioid receptor antagonist 1
  • HY-170658
    AChE-IN-80 98%
    AChE-IN-80 (Compound 1) is an acetylcholinesterase (AChE) inhibitor. AChE-IN-80 can inhibit inflammation and the production of reactive oxygen species (ROS) in vitro- cultured neurons and microglia, trigger autophagy responses, and block the propagation of β-amyloid (Aβ) fibrils. AChE-IN-80 possesses antioxidant activity and neuroprotective effects and can be used in the study of Alzheimer's disease.
    AChE-IN-80
  • HY-170687
    AT2R-IN-1 2896132-06-0 98%
    AT2R-IN-1 (A-174) is a AT2R inhibitor, used in the research of neuropathic pain.
    AT2R-IN-1
  • HY-170691
    hAChE/hBuChE-IN-1 98%
    hAChE/hBuChE-IN-1 (compound C2) is a dual inhibitor of cholinesterase with IC50 values of 514 nM and 358 nM for hAChE and hBuChE respectively. hAChE/hBuChE-IN-1 has oral activity and improves cognition and spatial memory.
    hAChE/hBuChE-IN-1
  • HY-170738
    Oudenone derivative-1 potassium 34200-97-0 98%
    Oudenone derivative-1 potassium is a derivative of Oudenone. Oudenone, a metabolite of the fungus, is a catecholamine biosynthesis and tyrosine hydroxylases inhibitor.
    Oudenone derivative-1 potassium
  • HY-170771
    α5-GABAA receptor modulator 1 98%
    α5-GABAA receptor modulator 1 (Compound A-4) is a silencing allosteric modulator (SAM) specifically targeting the a5 subunit of the GABAA receptor, suitable for research into central nervous system (CNS) disorders.
    α5-GABAA receptor modulator 1
  • HY-170789
    H1R ligand-1 19642-70-7 98%
    H1R ligand-1 (Compound fragment 1) is a high-affinity ligand for the human histamine H1 receptor (H1R). H1R ligand-1 can be used as a scaffold to design and synthesize a set of derivatives to explore H1R binding kinetics.
    H1R ligand-1
  • HY-170790
    HZS60 3027529-88-7 98%
    HZS60 is a NMDAR/TRPM4 inhibitor with brain permeability that can improve cerebral ischemia. HZS60 has significant neuroprotective effects on primary neuronal ischemic damage caused by NMDA and oxygen-glucose deprivation/reoxygenation. HZS60 exhibits good pharmacokinetic characteristics and can inhibit cerebral ischemia-reperfusion injury. HZS60 can be used as a potential inhibitor of ischemic stroke.
    HZS60
  • HY-170798
    Monoamine Oxidase B inhibitor 6 101091-29-6 98%
    Monoamine Oxidase B inhibitor 6 (Compound BT5) is a BBB-penetrable, highly selective, reversible and competitive MAO-B inhibitor, with an IC50 of 0.11 μM. Monoamine Oxidase B inhibitor 6 has antioxidant and neuroprotective effects and can be used in the research of neurodegenerative diseases.
    Monoamine Oxidase B inhibitor 6
Cat. No. Product Name / Synonyms Application Reactivity